Profile data is unavailable for this security.
About the company
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
- Revenue in USD (TTM)45.60m
- Net income in USD-35.74m
- Incorporated1998
- Employees143.00
- LocationMaxCyte Inc9713 KEY WEST AVENUE,, SUITE 400ROCKVILLE 20850United StatesUSA
- Phone+1 (301) 517-5556
- Fax+1 (301) 944-1703
- Websitehttps://www.maxcyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zynex Inc | 193.67m | 4.82m | 263.04m | 1.10k | 55.78 | 7.47 | 28.13 | 1.36 | 0.1481 | 0.1481 | 5.91 | 1.11 | 1.40 | 2.57 | 7.05 | 176,059.10 | 3.48 | 14.58 | 4.06 | 17.52 | 80.20 | 79.62 | 2.49 | 10.44 | 3.15 | 4.15 | 0.6246 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Pulmonx Corp | 79.30m | -57.11m | 268.12m | 279.00 | -- | 2.85 | -- | 3.38 | -1.47 | -1.47 | 2.04 | 2.38 | 0.45 | 1.24 | 7.29 | 284,236.60 | -32.41 | -26.27 | -36.42 | -28.97 | 74.16 | 71.95 | -72.01 | -93.76 | 6.77 | -- | 0.2839 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| AngioDynamics, Inc. | 292.73m | -243.03m | 277.53m | 748.00 | -- | 1.42 | -- | 0.9481 | -6.04 | -6.04 | 7.25 | 4.79 | 0.7434 | 2.27 | 6.55 | 391,344.90 | -61.72 | -16.38 | -74.39 | -18.70 | 51.71 | 52.95 | -83.02 | -30.49 | 1.41 | -- | 0.00 | -- | -10.28 | 2.35 | -251.53 | -- | 13.09 | -- |
| OraSure Technologies, Inc. | 224.26m | 11.37m | 289.43m | 638.00 | 25.77 | 0.6801 | 11.82 | 1.29 | 0.1506 | 0.1506 | 3.01 | 5.71 | 0.4862 | 2.64 | 5.58 | 351,509.40 | 2.72 | 0.7238 | 2.94 | 0.8212 | 42.26 | 46.94 | 5.59 | 1.13 | 11.20 | -- | 0.0004 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
| Neuropace Inc | 76.45m | -28.09m | 289.53m | 171.00 | -- | 29.41 | -- | 3.79 | -0.9924 | -0.9924 | 2.70 | 0.3299 | 0.7817 | 1.83 | 6.69 | 447,087.70 | -28.72 | -- | -33.44 | -- | 73.83 | -- | -36.74 | -- | 4.77 | -4.06 | 0.8578 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| Delcath Systems Inc | 22.64m | -34.12m | 312.06m | 76.00 | -- | 31.91 | -- | 13.78 | -1.36 | -1.36 | 0.8343 | 0.3059 | 0.5714 | 0.9094 | 6.34 | 297,947.40 | -86.11 | -116.57 | -156.17 | -243.21 | 81.31 | 71.02 | -150.70 | -1,235.37 | 1.03 | -172.60 | 0.1892 | -- | -24.05 | -9.53 | -30.60 | -- | -5.26 | -- |
| Clearpoint Neuro Inc | 30.43m | -18.15m | 326.46m | 107.00 | -- | 11.26 | -- | 10.73 | -0.6912 | -0.6912 | 1.16 | 1.05 | 0.7242 | 1.50 | 9.66 | 284,383.20 | -43.19 | -34.75 | -51.20 | -39.67 | 60.38 | 64.75 | -59.64 | -76.91 | 3.61 | -- | 0.00 | -- | 16.56 | 26.64 | -34.40 | -- | 75.30 | -- |
| Cerus Corp | 197.91m | -19.73m | 332.43m | 288.00 | -- | 6.21 | -- | 1.68 | -0.1076 | -0.1076 | 1.08 | 0.2882 | 1.00 | 1.97 | 7.88 | 687,194.40 | -10.01 | -25.99 | -15.26 | -40.62 | 60.52 | 61.90 | -10.00 | -35.81 | 1.92 | -1.19 | 0.6057 | -- | -0.8061 | 19.69 | 12.37 | -- | 32.07 | -- |
| CVRx Inc | 47.26m | -58.48m | 360.32m | 200.00 | -- | 5.51 | -- | 7.62 | -2.71 | -2.71 | 2.19 | 2.69 | 0.4038 | 0.657 | 6.14 | 236,275.00 | -49.96 | -- | -54.21 | -- | 84.16 | -- | -123.75 | -- | 10.23 | -17.04 | 0.4302 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Nano-X Imaging Ltd | 10.13m | -57.47m | 372.04m | 164.00 | -- | 2.12 | -- | 36.73 | -0.9974 | -0.9974 | 0.1755 | 2.99 | 0.0482 | -- | 6.89 | 61,756.10 | -27.33 | -30.98 | -29.96 | -35.10 | -81.80 | -- | -567.41 | -1,527.24 | 5.09 | -- | 0.0181 | -- | 15.47 | -- | 46.33 | -- | 114.35 | -- |
| MaxCyte Inc | 45.60m | -35.74m | 374.46m | 143.00 | -- | 1.75 | -- | 8.21 | -0.3420 | -0.3420 | 0.4368 | 2.03 | 0.177 | 0.5576 | 7.17 | 318,878.30 | -13.87 | -13.18 | -14.86 | -14.33 | 85.98 | 88.79 | -78.37 | -62.96 | 9.22 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Alpha Teknova Inc | 36.35m | -31.68m | 390.75m | 210.00 | -- | 4.48 | -- | 10.75 | -0.7366 | -0.7366 | 0.834 | 1.64 | 0.2770 | 3.12 | 7.44 | 173,081.00 | -24.14 | -- | -25.92 | -- | 17.71 | -- | -87.17 | -- | 3.94 | -75.86 | 0.133 | -- | -11.43 | -- | 22.52 | -- | -- | -- |
| ZimVie Inc | 451.30m | -47.73m | 391.08m | 2.60k | -- | 0.9613 | -- | 0.8666 | -1.77 | -13.16 | 16.60 | 14.74 | 0.394 | 1.14 | 4.04 | 173,575.00 | -4.17 | -- | -4.81 | -- | 63.18 | 65.51 | -10.58 | -8.73 | 1.38 | -0.6264 | 0.3514 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Tactile Systems Technology Inc | 285.05m | 15.45m | 428.35m | 992.00 | 27.76 | 2.06 | 19.34 | 1.50 | 0.643 | 0.643 | 11.91 | 8.66 | 0.9812 | 6.20 | 6.80 | 287,349.80 | 5.32 | 0.9015 | 6.20 | 1.09 | 51.44 | 49.10 | 5.42 | 0.8309 | 3.80 | -- | 0.1146 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Quanterix Corp | 129.33m | -39.71m | 450.95m | 441.00 | -- | 1.34 | -- | 3.49 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Semler Scientific Inc | 58.94m | 15.91m | 462.50m | 92.00 | 31.06 | 5.31 | 27.94 | 7.85 | 2.05 | 2.05 | 7.58 | 11.99 | 0.6868 | 17.20 | 9.33 | 640,619.60 | 18.54 | 38.83 | 20.37 | 44.41 | 88.05 | 90.22 | 27.00 | 32.58 | 3.09 | -- | 0.00 | -- | 20.28 | 25.98 | 43.69 | 32.64 | -0.3821 | -- |
Data as of Nov 25 2024. Currency figures normalised to MaxCyte Inc's reporting currency: US Dollar USD
41.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cadian Capital Management LPas of 30 Sep 2024 | 8.19m | 7.79% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 7.57m | 7.20% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 5.61m | 5.34% |
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 4.50m | 4.28% |
| Millennium Management LLCas of 30 Sep 2024 | 4.19m | 3.99% |
| Mudita Advisors LLPas of 30 Sep 2024 | 3.15m | 3.00% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 2.77m | 2.64% |
| Canaccord Genuity Wealth Ltd.as of 30 Apr 2024 | 2.51m | 2.39% |
| Unicorn Asset Management Ltd.as of 31 Oct 2024 | 2.49m | 2.37% |
| Geode Capital Management LLCas of 30 Sep 2024 | 2.47m | 2.36% |
More ▼
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
